Alliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Alliancebernstein L.P. lifted its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 751.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 199,259 shares of the company's stock after acquiring an additional 175,859 shares during the quarter. Alliancebernstein L.P. owned 0.85% of UroGen Pharma worth $2,122,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in URGN. KLP Kapitalforvaltning AS purchased a new stake in UroGen Pharma in the fourth quarter worth approximately $59,000. BNP Paribas Financial Markets grew its holdings in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock worth $109,000 after acquiring an additional 5,890 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in UroGen Pharma during the fourth quarter valued at $126,000. SG Americas Securities LLC lifted its holdings in UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock valued at $216,000 after acquiring an additional 6,207 shares during the period. Finally, FMR LLC boosted its position in UroGen Pharma by 575.1% in the third quarter. FMR LLC now owns 23,090 shares of the company's stock worth $293,000 after purchasing an additional 19,670 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Stock Down 3.3 %

Shares of URGN stock opened at $10.39 on Thursday. The company has a market capitalization of $478.92 million, a price-to-earnings ratio of -3.30 and a beta of 0.80. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company's fifty day moving average price is $10.52 and its 200-day moving average price is $11.23. UroGen Pharma Ltd. has a one year low of $8.94 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Sell-side analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Scotiabank started coverage on shares of UroGen Pharma in a research note on Wednesday. They issued a "sector outperform" rating and a $23.00 price objective on the stock. HC Wainwright decreased their price target on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. Finally, LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, UroGen Pharma has a consensus rating of "Buy" and an average price target of $35.67.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 4,551 shares of the business's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company's stock, valued at $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.